EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

RIPK3 inhibitor GSK872 targets angiotensin II induced cardiomyocyte hypertrophy by regulating Ca2+/ calmodulin dependent protein kinase II

Jingjing Zhang, Huijie Yu, Yuxin Yang, Ajie Liu, Peng Wang iD

PLOS One · 07.01.2026 · 21 (1) · e0334387

DOI: 10.1371/journal.pone.0334387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 07.01.2026. Verfasst von Jingjing Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, People's Republic of China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Calcium-Calmodulin-Dependent Protein Kinase Type 2, Angiotensin II, Receptor-Interacting Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Provincial Research Hospital Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Receptor interacting protein kinase 3 (RIPK3) plays a crucial role in the signaling pathway of necrotic apoptosis, and calcium/calmodulin dependent protein kinase II (CaMKII) is a novel substrate for RIPK3 induced regulated necrosis. The aim of this study is to investigate the regulation and mechanism of RIPK3 on AngII induced cardiomyocyte hypertrophy. Using AngII to stimulate myocardial cells for 72 hours, inducing myocardial cell hypertrophy; Intervention of RIPK3 expression using RIPK3 inhibitor GSK872. Detect indicators related to myocardial hypertrophy, cell damage, regulatory necrosis, CaMKII activation and gene expression, oxidative stress, mitochondrial membrane potential, etc. After AngII stimulation of cardiomyocytes, the expression of hypertrophy markers ANP and BNP increased, LDH release increased, ATP levels decreased, splicing factors ASF and SC35 expression increased, CaMKII oxidation and phosphorylation levels increased, and CaMKIIδ alternative splicing was disrupted. However, treatment with GSK872 can alleviate myocardial dysfunction, inhibit CaMKII activation, correct CaMKIIδ variant splicing disorder and ultimately alleviating myocardial hypertrophy. In addition, pretreatment with RIPK3 can reduce the accumulation of reactive oxygen species (ROS) induced by AngII, decrease the activity of ASF and SC35, and restore mitochondrial membrane potential. RIPK3 inhibitor GSK872 can inhibit the activation of CaMKII, alleviate regulated necrosis and oxidative stress to alleviate myocardial hypertrophy. It has a protective effect on myocardial hypertrophy and is expected to become a new targeted drug for clinical treatment of dilated cardiomyopathy and heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacCalcium-Calmodulin-Dependent Protein Kinase Type 2Angiotensin IIReceptor-Interacting Protein Serine-Threonine KinasesCardiomegalyProtein Kinase InhibitorsAnimalsReactive Oxygen SpeciesMembrane Potential, MitochondrialOxidative StressRats

Substanzen

Calcium-Calmodulin-Dependent Protein Kinase Type 2Angiotensin IIReactive Oxygen SpeciesReceptor-Interacting Protein Serine-Threonine KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, People's Republic of China.

ORCID-Profile: Peng Wang

Förderung

  • Jiangsu Provincial Research Hospital Fund

Zitieren

APA

Zhang, J., Yu, H., Yang, Y., Liu, A., & Wang, P. (2026). RIPK3 inhibitor GSK872 targets angiotensin II induced cardiomyocyte hypertrophy by regulating Ca2+/ calmodulin dependent protein kinase II. PLOS One, 21(1), e0334387. https://doi.org/10.1371/journal.pone.0334387

Vancouver

Zhang J, Yu H, Yang Y, Liu A, Wang P. RIPK3 inhibitor GSK872 targets angiotensin II induced cardiomyocyte hypertrophy by regulating Ca2+/ calmodulin dependent protein kinase II. PLOS One. 2026;21(1):e0334387. doi:10.1371/journal.pone.0334387

BibTeX
@article{Zhang2026,
  author = {Zhang, Jingjing and Yu, Huijie and Yang, Yuxin and Liu, Ajie and Wang, Peng},
  title = {RIPK3 inhibitor GSK872 targets angiotensin II induced cardiomyocyte hypertrophy by regulating Ca2+/ calmodulin dependent protein kinase II},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {1},
  pages = {e0334387},
  doi = {10.1371/journal.pone.0334387}
}
Kostenlos starten →